(CercleFinance.com) – AB Science announces that it has entered into an agreement with a historical investor for financing through the issuance of bonds convertible into new ordinary shares (OCA) to which stock warrants (BSA) are attached.
The issue involves 50,000 OCABSAs, representing a bond loan of 8.5 million dollars. It strengthens AB Science’s cash position for the development of its clinical research program.
The issue of the OCABSA will be carried out no later than March 7. The biopharmaceutical company specifies that the OCAs will not be the subject of a request for admission to trading on Euronext Paris, and will therefore not be listed.